关节止痛注射市场规模、份额、成长分析，按类型、关节、最终用途、地区 - 产业预测，2024-2031

2022年全球关节疼痛注射市场规模估值为63亿美元，从2023年的67.9亿美元增长到2031年的122.8亿美元，在预测期内（2024-2031年）预计复合年增长率为7.7。 。

由于关节疾病盛行率上升、人口老化以及对微创治疗的需求不断增加，全球关节疼痛注射市场预计将显着成长。这些注射不仅可以缓解针对性疼痛，还可以增强关节功能，使其成为手术的理想替代方案。旨在提高功效和寿命的注射技术和新配方的创新正在进一步推动市场扩张。再生医学和生物注射疗法的日益接受度也正在改变市场动态。然而，高成本、有限的报销选择和潜在副作用等挑战可能会阻碍未来的成长前景。总体而言，由于不断变化的患者需求和技术进步，该行业提供了巨大的商机。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

关节痛注射剂市场规模：按类型

• 市场概况
• 玻尿酸注射
• 皮质类固醇注射
• 富血小板血浆注射
• 其他的

关节痛注射剂市场规模：依关节分类

• 市场概况
• 膝盖
• 肩膀和肘部
• 脚踝和臀部
• 其他接头类型

关节痛注射剂市场规模：依最终用途分类

• 市场概况
• 医院
• 诊所
• 其他的

关节痛注射剂市场规模：依地区划分

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Pfizer Inc.（USA）
• AbbVie Inc.（USA）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sanofi（France）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Seikagaku Corporation（Japan）
• Anika Therapeutics, Inc.（USA）
• Ferring BV（Netherlands）
• Bioventus（USA）
• Flexion Therapeutics, Inc.（USA）
• Zimmer Biomet Holdings, Inc.（USA）
• Smith & Nephew plc（UK）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）

结论和建议

Global Joint Pain Injections Market size was valued at USD 6.3 billion in 2022 and is poised to grow from USD 6.79 billion in 2023 to USD 12.28 billion by 2031, growing at a CAGR of 7.7% during the forecast period (2024-2031).

The global Joint Pain Injections market is poised for substantial growth, fueled by a rising incidence of joint disorders, an aging population, and an escalating demand for minimally invasive treatments. These injections not only deliver targeted pain relief but also enhance joint functionality, serving as a preferable alternative to surgery. Innovations in injection technologies and novel formulations aimed at improving efficacy and longevity are further propelling market expansion. The increasing acceptance of regenerative medicine and biologic injection therapies is also transforming the market dynamics. Nonetheless, challenges such as high costs, limited reimbursement options, and potential side effects could impede future growth prospects. Overall, this sector presents significant opportunities driven by evolving patient needs and technological advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Joint Pain Injections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Joint Pain Injections Market Segmental Analysis

Global Joint Pain Injections Market is segmented by type, joint, end use and region. Based on type, the market is segmented into hyaluronic acid injections, corticosteroid injections, platelet rich plasma injections and others. Based on joint, the market is segmented into knee, shoulder & elbow, ankle & hip and other joint types. Based on end use, the market is segmented into hospitals, clinics and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Joint Pain Injections Market

A key factor propelling the global Joint Pain Injections market is the rising prevalence of joint-related disorders. The escalating rates of conditions like osteoarthritis and rheumatoid arthritis have led to heightened demand for efficient pain relief treatments, particularly joint pain injections. Additionally, the aging population, coupled with increasingly sedentary lifestyles and the frequency of sports-related injuries, further fuels this market expansion. As more individuals seek effective methods to manage their joint pain, the market for joint pain injections continues to grow, reflecting a significant need for innovative and targeted therapeutic options in the healthcare landscape.

Restraints in the Global Joint Pain Injections Market

One significant restraint on the global Joint Pain Injections market is the elevated cost associated with these treatments. For many individuals, particularly those lacking adequate insurance coverage, the price of joint pain injections can be prohibitively high. This financial barrier restricts access to necessary treatment options for patients, notably in developing regions where healthcare affordability poses a considerable challenge. Furthermore, the reimbursement policies and regulatory obstacles present in certain countries can further impede market expansion, limiting the availability and acceptance of joint pain injections among potential users. Overall, these factors contribute to a constrained market environment.

Market Trends of the Global Joint Pain Injections Market

The global Joint Pain Injections market is witnessing a significant trend towards the adoption of minimally invasive procedures, driven by a burgeoning demand for non-surgical treatment options among patients and healthcare providers. This shift towards injections is fueled by their advantages, such as quicker recovery times, lower complication risks, and reduced postoperative discomfort. Administered in outpatient settings, these injections deliver targeted pain relief directly to the affected joints, enhancing patient comfort and satisfaction. Furthermore, the trend reflects a broader movement towards personalized and patient-centric care, enabling customized treatment plans that cater to individual patient needs and preferences, ultimately fostering a more proactive approach to managing joint pain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Joint Pain Injections Market Size by Type & CAGR (2024-2031)

• Market Overview
• Hyaluronic Acid Injections
• Corticosteroid Injections
• Platelet Rich Plasma Injections
• Others

Global Joint Pain Injections Market Size by Joint & CAGR (2024-2031)

• Market Overview
• Knee
• Shoulder & Elbow
• Ankle & Hip
• Other Joint Types

Global Joint Pain Injections Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Other

Global Joint Pain Injections Market Size & CAGR (2024-2031)

• North America (Type, Joint, End Use)
  • USA
  • Canada
• Europe (Type, Joint, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Joint, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Joint, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Joint, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioventus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations